Barclays PLC Intra Cellular Therapies, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Barclays PLC holds 34,453 shares of ITCI stock, worth $3.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,453

Previous 34,453 -0.0%

Holding current value

$3.27 Million

Previous $2.52 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$67.99 - $80.84 $1.73 Million - $2.06 Million	25,435 Added 282.05%	34,453 $2.52 Million
Q2 2024 Aug 14, 2024	SELL	$64.76 - $79.84 $5.4 Million - $6.66 Million	-83,403 Reduced 90.24%	9,018 $618,000
Q1 2024 May 15, 2024	SELL	$64.37 - $75.65 $7.41 Million - $8.71 Million	-115,093 Reduced 55.46%	92,421 $6.4 Million
Q4 2023 Feb 15, 2024	BUY	$46.37 - $73.65 $6.67 Million - $10.6 Million	143,826 Added 225.83%	207,514 $14.9 Million
Q3 2023 Nov 07, 2023	BUY	$52.09 - $64.1 $1.13 Million - $1.39 Million	21,643 Added 51.48%	63,688 $3.32 Million
Q2 2023 Aug 03, 2023	SELL	$54.67 - $66.44 $10.8 Million - $13.1 Million	-197,791 Reduced 82.47%	42,045 $2.66 Million
Q1 2023 May 04, 2023	BUY	$43.8 - $56.99 $2.2 Million - $2.87 Million	50,307 Added 26.54%	239,836 $13 Million
Q4 2022 Feb 13, 2023	BUY	$44.07 - $54.45 $5.47 Million - $6.76 Million	124,090 Added 189.63%	189,529 $10 Million
Q3 2022 Nov 03, 2022	BUY	$42.7 - $59.99 $1.63 Million - $2.3 Million	38,286 Added 141.0%	65,439 $3.04 Million
Q2 2022 Aug 12, 2022	SELL	$43.0 - $65.64 $459,197 - $700,969	-10,679 Reduced 28.23%	27,153 $1.55 Million
Q1 2022 May 16, 2022	SELL	$38.74 - $62.09 $2.52 Million - $4.04 Million	-65,138 Reduced 63.26%	37,832 $2.32 Million
Q4 2021 Feb 14, 2022	BUY	$35.2 - $53.42 $2.04 Million - $3.09 Million	57,867 Added 128.3%	102,970 $5.39 Million
Q3 2021 Nov 09, 2021	BUY	$28.72 - $42.49 $793,591 - $1.17 Million	27,632 Added 158.16%	45,103 $1.68 Million
Q2 2021 Aug 13, 2021	SELL	$29.3 - $44.5 $2.25 Million - $3.42 Million	-76,894 Reduced 81.49%	17,471 $714,000
Q1 2021 May 13, 2021	SELL	$30.8 - $39.51 $1.92 Million - $2.46 Million	-62,365 Reduced 39.79%	94,365 $3.2 Million
Q4 2020 Feb 11, 2021	BUY	$23.34 - $32.22 $317,750 - $438,643	13,614 Added 9.51%	156,730 $4.98 Million
Q3 2020 Nov 12, 2020	BUY	$17.61 - $31.86 $922,658 - $1.67 Million	52,394 Added 57.75%	143,116 $3.67 Million
Q2 2020 Aug 12, 2020	BUY	$14.35 - $26.64 $977,249 - $1.81 Million	68,101 Added 301.05%	90,722 $2.33 Million
Q1 2020 May 13, 2020	SELL	$12.31 - $33.12 $596,751 - $1.61 Million	-48,477 Reduced 68.18%	22,621 $349,000
Q4 2019 Feb 10, 2020	BUY	$7.26 - $38.49 $274,195 - $1.45 Million	37,768 Added 113.32%	71,098 $2.44 Million
Q3 2019 Nov 14, 2019	SELL	$7.47 - $14.03 $49,182 - $92,373	-6,584 Reduced 16.5%	33,330 $249,000
Q2 2019 Aug 14, 2019	BUY	$10.65 - $14.29 $151,847 - $203,746	14,258 Added 55.57%	39,914 $518,000
Q1 2019 May 15, 2019	BUY	$10.9 - $14.09 $40,384 - $52,203	3,705 Added 16.88%	25,656 $313,000
Q4 2018 Feb 14, 2019	SELL	$10.36 - $20.96 $56,462 - $114,232	-5,450 Reduced 19.89%	21,951 $250,000
Q3 2018 Nov 14, 2018	BUY	$17.77 - $22.9 $428,612 - $552,348	24,120 Added 735.14%	27,401 $594,000
Q2 2018 Aug 14, 2018	SELL	$17.33 - $23.4 $130,460 - $176,155	-7,528 Reduced 69.65%	3,281 $58,000
Q1 2018 May 15, 2018	SELL	$15.16 - $25.49 $299,531 - $503,631	-19,758 Reduced 64.64%	10,809 $228,000
Q4 2017 Feb 14, 2018	SELL	$14.27 - $16.79 $485,622 - $571,380	-34,031 Reduced 52.68%	30,567 $442,000
Q3 2017 Nov 14, 2017	BUY	$10.77 - $22.1 $695,720 - $1.43 Million	64,598	64,598 $1.02 Million

Others Institutions Holding ITCI

# of Institutions

379

Shares Held

84.1M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.96B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account